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HIV vaccine trials in humans have shown variability in vaccine responses among individuals. 
The SIV:macaque  model  can  be used  to  understand  the outcome of  HIV  vaccine trials  in 
humans, specifically, the role of the innate immune system in inducing protective immunity. 
CXCL13, CCL20, CCL1, CCL2, CCL5, and TRIM5α, molecules of the innate immune system, 
were selected as part of a study into the relationship between these molecules and vaccine 
response.  Sequence variation in the innate immune genes was determined in 25 rhesus macaques 
that were part of a SIV vaccine trial, a multiple low dose exposure study, or a control group. 
PCR primers were designed, based on the published rhesus macaque genome, to amplify 
approximately 2 kilobases of promoter region and the exons of the genes.  Each amplicon was 
sequenced in at least 8 animals, and the sequences were visually screened for single nucleotide 
polymorphisms (SNPs). Numerous SNPs were detected in all of these genes.  Statistical analysis 
showed that there was no correlation between polymorphisms in these genes and protection 
against SIV challenge.  Copy number variation (CNV) was also examined in these genes using 
either custom TaqMan copy number assays or SYBR Green assays and quantitative real-time 
PCR.  The results of the TaqMan assay indicate that CXCL13 demonstrates CNV.  Genetic 
variation in these innate immune genes is likely not important in rhesus macaque response to 
SIV challenge, although larger studies are needed to provide more definitive results. The public 
Health significance of this study is that understanding genetic factors that influence macaque 
iv 
5  
responses to vaccination or SIV challenge will help us to understand HIV in humans with the 
goal of developing a more effective vaccine and the ability to predict individual’s susceptibility 
to disease or response to vaccination. 
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1.0  INTRODUCTION 
1.1 HUMAN IMMUNODEFICIENCY VIRUS 
1.1.1 Epidemiology 
Human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency 
syndrome (AIDS), which is one of the most important global epidemics of our time.  Currently, 
over 34 million people live with HIV worldwide.  In 2010, 2.7 million people became infected 
with HIV, and 1.8 million people died of AIDS(61).  It is the leading cause of death in Africa, 
and the fourth leading cause of death worldwide(53). 
1.1.2 Infection 
HIV is a blood-borne pathogen and can be transmitted via several modes including mother to 
child, needle sharing among injection drug users, receiving contaminated blood products, or 
sexual transmission(17, 53).  Initially the viral glycoprotein, gp120, attaches to the cellular 
receptor CD4 which is primarily found on helper T cells and macrophages.  This binding is 
necessary, but it is insufficient for viral entry.  The virus must also bind to a coreceptor. Most 
sexually transmitted HIV strains use the CCR5 coreceptor that is found on memory CD4+ T cells 
and macrophages.  In some cases, the virus will use CXCR4 as a coreceptor which is found on 
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many T cells and macrophages.  CXCR4 becomes more important later in infection as the virus 
shifts its tropism to this coreceptor.   Once the virus has established infection, there is a period of 
rapid viral replication during which CD4+ T cells of the mucosa are depleted(17, 28, 53, 56).  
Peak viremia usually occurs about 10-14 days after infection.  At about 14-21 days, a robust 
antiviral cytotoxic T lymphocyte (CTL) response is observed, and plasma viral titers decrease.  
Virus specific antibodies emerge later around 6-8 weeks after infection.  This HIV-specific 
immune response helps set a plasma viral load, or set point, that is a predictor of the rate of 
progression to AIDS.  Although the virus elicits a strong cellular and humoral immune response, 
it is not enough to clear the host of the virus.  The highly error-prone reverse transcriptase 
enzyme of HIV introduces mutations into the viral genome resulting in escape mutants that are 
able to evade the immune system and antiretroviral drugs(28, 53, 56). 
1.1.3 Origin 
It is thought that the origin of HIV was from lentiviruses that infected primate species in Africa.  
There are two strains of HIV that exist today, HIV-1 and HIV-2.  HIV-2 infection is far less 
common and less pathogenic(53).  It is thought that SIVsm, which naturally infects sooty 
mangabeys (Cercocebus atys) in West Africa, infected humans about 50-60 years ago and 
evolved into HIV-2.  This hypothesis is supported because sooty mangabeys that are naturally 
infected by SIVsm live in West Africa, HIV-2 infection of humans is prevalent in West Africa, 
and the genetic sequences of SIVsm and HIV-2 share a high degree of homology(21).  HIV-1 
infection of humans is more common than HIV-2 and is the primary cause of AIDS(53).  The 
exact origin of HIV-1 is less obvious, but it is widely accepted that it also originated from an 
African primate lentivirus(53).  Because HIV-1 can be further divided into different subtypes, it 
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is hypothesized that HIV-1 actually originated via several independent infections of humans by 
primate lentiviruses.  Strains of SIVcpz from chimpanzees in Gabon are genetically similar to 
HIV-1, thus it is accepted that HIV-1 originated through cross-species transmission of SIVcpz 
from chimpanzees to humans(57). 
1.2 SIMIAN IMMUNODEFICIENCY VIRUS 
1.2.1 Pathogenic vs. Non-pathogenic Infection 
Lentivirus infections of nonhuman primates have provided us with models to understand HIV 
pathogenesis better in humans.  With regard to disease, two models of SIV infection exist: 
nonpathogenic and pathogenic.  In Africa, dozens of species of primates are infected with 
species-specific lentiviruses(32). SIV infection of these natural hosts, including sooty 
mangabeys, African green monkeys, chimpanzees, and mandrills is typically nonpathogenic.  
Although these animals become infected and sustain high viral replication, they remain healthy 
and do not progress to AIDS.  However, infection of Asian-origin primates (non-natural hosts), 
such as rhesus macaques, with SIV is pathogenic and often leads to the progression of AIDS(6, 
7, 51).   
1.2.1.1 Acute Infection 
Although pathogenic and non-pathogenic SIV models represent infection that results in different 
disease outcomes, they share many similarities, especially during acute infection.  In both 
models, acute infection is associated with rapid viral replication with peak virus titers occurring 
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about 1-2 weeks post infection.  Virus levels then dramatically decline, usually by 2 log10 or 
more(7, 51).  Acute infection is also characterized by a strong innate immune response to the 
virus.  In the blood and in lymphoid tissues there is an upregulation of interferon-stimulated 
genes (ISGs)(6, 32).  Both models also show elevated levels of CD8+ T cell apoptosis(32).  
Additionally, activated CD4+ T cells that express the coreceptor CCR5 are the main target cells 
that support viral replication, and subsequently become depleted.  In both models, the majority of 
the depletion of these CD4+ T cells occurs in the mucosa.  Thus, viral replication kinetics and 
CD4+ T cell deletion during acute infection does not explain the difference in disease outcome 
between African and Asian nonhuman primates (7, 51). 
1.2.1.2 Key Differences between Pathogenic and Non-pathogenic SIV infection 
There are, however, key differences between pathogenic and non-pathogenic SIV infection.  
During non-pathogenic infection peripheral CD4+ T cell levels do not decline, there is less 
immune activation, and there is less expression of CCR5 on CD4+ T cells(7).  In the vast 
majority of natural SIV infections the host maintains near normal levels of peripheral CD4+ T 
cells, although mucosal CD4+ T cells are depleted during acute infection(6, 7, 32, 51).  Even in 
the small fraction of natural SIV infections that result in severe peripheral CD4+ T cell depletion, 
the animals do not progress to AIDS(51).  Of note, natural hosts are able to preserve near normal 
levels of Th17 T cells in the gut, which may play an important role in preventing progression to 
AIDS(7, 32).   
1.2.1.3 Chronic Infection 
Although immune responses during acute infection is strikingly similar in pathogenic and non-
pathogenic SIV infection, the level of immune activation during chronic infection is quite 
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different.  In the pathogenic model, animals maintain a high level of immune activation 
throughout the chronic stage of infection.  There are high levels of T cell turnover, activation, 
and apoptosis(7).  This chronic immune activation is thought to affect CD4+ T cell homeostasis 
and immune function by increasing the number of CD4+ T cells that can be targeted by the virus, 
exhaustion of CD8+ T cells, abnormal T cell apoptosis, and suppression of lymphocyte 
regeneration(6).  Natural hosts, on the other hand, demonstrate little immune activation after 
acute infection.  Specifically, they show lower levels of bystander apoptosis and cell cycle 
dysregulation(51).  The mechanisms that underlie this low level of immune activation in the face 
of viral replication is not well understood, but it is suspected that it is one of the key features of 
natural infection that protects these animals from progressing to AIDS.  The proportion of CD4+ 
T cells expressing CCR5 is quite different between pathogenic and non-pathogenic models.  In 
non-natural hosts (and humans) about 10-20% of CD4+ T cells in the blood and more than 50% 
in the mucosa express CCR5.  In natural hosts, however, only about 1-5% of CD4+ T cells in 
both the blood and mucosa express CCR5.  Although this lower expression of CCR5 does not 
protect natural hosts from becoming infected, nor does it prevent viral replication, it may play a 
role in maintaining CD4+ T cell homeostatsis(7, 32, 51). 
1.2.1.4 Relevance to HIV research 
Both pathogenic and non-pathogenic models of SIV infection are important in understanding 
HIV pathogenesis and disease progression.  The natural host model can help us to better 
understand the immunological factors that promote a non-progressive form of infection, while 
non-natural hosts (such as rhesus macaques) provide a valuable animal model that closely 
mimics HIV-1 infection in humans.  Macaque infection by SIV, and HIV-1 infection in humans 
share numerous similarities including infection by mainly CCR5-tropic viruses, severe and rapid 
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depletion of CD4+ T cells in the gut, viral replication in both activated and resting T cells, 
resolution of acute infection by antigen-specific immune response, viral immune evasion, 
sustained viral load in plasma after acute infection predicting disease progression, and peripheral 
CD4+ T cell depletion leads to progression to AIDS(22). 
1.2.2 SHIV 
Although the macaque:SIV model provides us with a good model of HIV-1 infection in humans, 
it is not a perfect representation.  For example, HIV-1 vaccines cannot be directly assessed in this 
model because at the DNA level SIV is about 80% homologous to HIV-2, and about 40-50% 
homologous to HIV-1.  Additionally, the strains of SIV used in macaque studies have been 
selected by researchers to be highly virulent and result in rapid progression to AIDs.  To help 
ameliorate some of these problems and make vaccine testing in macaques more relevant, HIV-
1/SIV chimeric viruses (SHIV) have been created.  Desired genes from HIV-1, such as tat, rev, 
vpu, and env, are introduced into the genome of a SIV strain.  Such SHIV strains usually 
demonstrate similar pathogenesis to SIV in the macaque model, but SHIV offers the advantage 
of allowing for HIV-1 vaccine testing(22). 
1.2.3 Vaccine Studies 
Macaques are also used in SIV vaccine studies.  These vaccine studies are designed to study the 
efficacy of different vaccine strategies that could be employed by future HIV-1 vaccines.  One 
vaccine strategy that has been tested in the macaque model is live-attenuated vaccines.  The 
vaccine of this model that has probably shown the most success is SIVmac239Δnef in which the 
 7 
nef gene has been deleted.  SIVmac239Δnef was able to protect adult animals from infection 
upon challenge with SIVmac239 or SIVmac251.  It was much less successful, however, in 
preventing infection by heterologous strains of SIV.  There are also safety concerns with live-
attenuated vaccines that make them a less than ideal candidate for HIV-1 vaccines (22).  Several 
prime-boost vaccine strategies have also been tested in macaques with varying success.  In the 
prime-boost strategy, the animal is first given a recombinant virus vector and then boosted with 
either protein subunits or DNA(22).  Other studies have shown promising results with the use of 
particle-mediated (PMED) DNA vaccines.  For example, Fuller and colleagues demonstrated 
that a SIV DNA vaccine resulted in protective immunity upon mucosal challenge with SIV in a 
number of monkeys.  This PMED DNA vaccine contained gag-pol-env sequences from SIV 
strain 17E-Fr.  Rhesus macaques were given multiple immunizations via the epidermis 12 – 14 
weeks apart.  Immunizations resulted in increased levels of cytotoxic T lymphocytes.  When 
challenged intrarectally with a high dose of SIV strain DeltaB670, four of seven vaccinated 
animals were protected against infection, while only one of 10 control animals did not become 
infected(16). 
1.2.4 Multiple Low Dose Exposure Studies 
Rhesus macaques have been used in several different experimental designs to study HIV-1 in 
humans.  Multiple low-dose exposure studies provide a useful model for sexual transmission of 
the virus in humans.  In most macaque vaccine studies, the monkeys are inoculated with high 
titer inocula to ensure consistent infection, because such animal studies are expensive and thus 
utilize a limited number of animals.  Such high titer inocula are not representative of sexual 
transmission, making multiple low dose exposure studies important to understanding sexual 
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transmission of HIV(22, 33).  Similarly, rhesus macaques have been shown to acquire protective 
immunity following multiple mucosal exposures to SIV.  In one multiple low dose challenge 
study, researchers administered several low dose challenges intrarectally to rhesus macaques.  
When these monkeys were then challenged with a high dose of SIV intrarectally, four out of 
eleven were resistant to infection compared to zero of four control animals(34). 
1.3 HUMAN VACCINE TRIALS 
Vaccine trials conducted in both macaques and humans have resulted in protective immunity in 
up to about 30% of individuals(24).  To date, there have been over 163 HIV-1 vaccine clinical 
trials conducted in humans(33).  Very few, however, have yielded promising results.  One such 
study was an HIV vaccine efficacy trial in Thailand where 16,402 healthy adults were either 
administered a placebo, or four priming shots of a recombinant canarypox vector vaccine and 
two booster shots of a recombinant glycoprotein 120 subunit vaccine (ALVAC-HIV [Vcp1521], 
and AIDSVAX B/E, respectively).  HIV-1 infection was monitored in this cohort at regular time 
intervals for three years.  At the conclusion of the study, the investigators found vaccine efficacy 
to be about 30%.  Although the vaccine showed a modest effect in preventing HIV-1 infection, it 
did not influence viral load or CD4+ T cell counts in those who became infected(33, 40).  The 
immunological mechanisms underlying the moderate success of this vaccine are unclear.  
Although neutralizing antibodies were not elicited by this vaccine, binding antibodies against the 
HIV-1 envelope were produced.  These antibodies may have promoted antibody-dependent cell-
mediate cytotoxicity, which may have afforded some protection against HIV-1.  The vaccine also 
did not elicit a CD8+ T cell response, although it did stimulate a strong CD4+ T cell 
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response(33).  Although the exact mechanisms of its action are unclear, this vaccine remains the 
most effective HIV-1 vaccine to date, eliciting protective immunity in about 30% of individuals. 
1.4 HOST GENETICS AND DISEASE 
1.4.1 Known Genetic Factors that Influence HIV-1 
In both humans and macaques, vaccines have conferred protective immunity in about one third 
of individuals.  The reason for this variability in vaccine response is not well understood, but one 
explanation may be host genetic factors.  Although host genetics are often overlooked in 
infectious diseases, they can greatly influence factors such as immunity and virus replication.  
For example, the CCR5Δ32 mutation in humans has been shown to profoundly influence HIV 
disease outcome.  CCR5 is the coreceptor used to gain entry into target cells by most transmitted 
strains of HIV-1, and is found on the surface of activated T cells as well as macrophages, 
dendritic cells, and microglial cells(52).  The CCR5Δ32 mutation is a 32 basepair deletion in the 
CCR5 gene that results in a frameshift that introduces a premature stop codon.  As a result, the 
CCR5 protein is truncated and not expressed on the cell surface, eliminating the coreceptor used 
by CCR5 tropic viruses.  People who are homozygous for this mutation are virtually resistant to 
infection by HIV while people who are heterozygous for the mutation tend to progress slower to 
AIDS by about 2-4 years(1, 9, 37, 52).  The CCR5Δ32 mutation is most common among 
northern Europeans at a frequency of about 15%(9) (although only 1% are homozygous for the 
mutation(1)).  It is also found at a frequency of 0-12% in different Asian populations, but is 
nearly absent among Africans(1, 9, 37, 52).  Alternatively, mutations within the same CCR5 
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gene are associated with more rapid progression to AIDS.  The promoter region of the gene 
contains a series of single nucleotide polymorphisms (SNPs) that have been organized into 
distinct haplotypes.  Individuals that are homozygous for the CCR5P1 allele progress to AIDS 
more quickly(9, 52). 
Chemokines produced by the host may also play a role in disease outcome.  These small 
proteins, produced by cells in the immune system, regulate the trafficking of other cells via 
chemotaxis.  Their targets are seven-transmembrane G-protein coupled receptors on cells of both 
the innate and adaptive immune systems including neutrophils, monocytes, and lymphocytes(39, 
59, 60).  Some chemokines, specifically β-chemokines, have been shown to greatly influence the 
outcome of HIV exposure.  The β-chemokines, MIP-1α (CCL3), MIP-1β (CCL4), and RANTES 
(CCL5) actually prevent the infection of CD4+ T cells by HIV.  These chemokines are the 
natural ligands of CCR5, the main coreceptor used by HIV-1 in viral entry.  Because they are 
ligands of CCR5, they compete with CCR5-tropic viruses for the receptor, thus blocking viral 
entry.  Several polymorphisms in these genes contribute to their levels of expression which 
correlate with rate of progression to AIDS(1, 37, 41). 
1.4.2 Single Nucleotide Polymorphisms (SNPs) 
Single nucleotide polymorphisms (SNPs) are a common type of genetic variation in the human 
genome that can influence disease.  SNPs are single basepair mutations in the DNA.  Typically 
they are biallelic, meaning there is either one of two possible nucleotides at the particular 
position.  A SNP can arise by one of two kinds of mutations, transitions or transversions.  
Transitions are purine to purine (adenine and guanine) or pyrimidine to pyrimidine (cytosine and 
thymine) mutations, while transversions are purine to pyrimidine or pyrimidine to purine 
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mutations.  Transition mutations are more common.  Most of these mutations are found in 
introns or between genes, and are not important.  If a SNP lies in an exon of a gene, it may result 
in an amino acid change, altering the protein.  Similarly, SNPs in promoter regions may affect 
the binding of transcription factors, varying the expression of the protein.  Although single 
basepair mutations are fairly common in the human genome, they are only considered SNPs if 
the minor allele frequency is at least 1% in the population(23).  So far, over 1.42 million SNPs 
have been detected in the human genome(23, 46).  Several of these SNPs have been shown to 
affect HIV-1 susceptibility and progression to AIDS.  The CCR2-V64I mutation is a guanine to 
adenine transition in the DNA that changes an amino acid from a valine to an isoleucine.  
Although the exact mechanism of action is unclear, this mutation is associated with a slower 
progression to AIDS.  Several SNPs within the gene encoding CCL5, a natural ligand for CCR5, 
alter the expression of the protein and affect the rate of progression to AIDS.  The In1.1C SNP in 
the intronic regulatory region of the gene decreases the expression of the protein and results in a 
more rapid progression to AIDS(1, 9, 37, 41).  These are just a few of the many SNPs that have 
been found to be associated with susceptibility to infection and progression to disease. 
1.4.3 Copy Number Variation (CNV) 
Another type of genetic variation that has been shown to influence disease in humans is copy 
number variation (CNV).  CNV is characterized by large deletions or duplications that involve 
DNA fragments of at least 1 kilobase that alter the number of copies of a gene in the 
genome(15).  Such CNV has been detected in the human genome, especially in genes involved in 
immunity.  CNV in some of these genes has been found to have effects on disease outcome.  
Probably the best characterized example in humans is CNV in CCL3L1 and the effect on HIV-1 
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infection and progression to AIDS(18).  As mentioned earlier, CCL3 (MIP-1α) is one of the 
natural ligands for CCR5, the primary coreceptor used by HIV-1(1, 37, 41). CCL3L1, or MIP-
1αP, is the copied isoform of the gene that encodes MIP-1α.  Like CCL3, CCL3L1 is also a 
ligand for CCR5, and is actually the most potent of the known ligands for this receptor.  
Examination of CNV in CCL3L1 revealed both interindividual and interpopulation variation.  
Low copy number of CCL3L1, relative to the geographic ancestral population mean, was 
associated with increased susceptibility to HIV-1 infection, and more rapid progression to AIDS.  
Alternatively, additional copies of the CCL3L1 gene, compared to the geographic ancestral 
population mean, were associated with a decreased risk of HIV-1 infection, and a slower 
progression to AIDS(18).  Similarly, CNV has been detected within the rhesus macaque 
genome(14, 29).  Like humans, CNV in CCL3-like genes correlates with rate of progression to 
AIDS(14).   
1.5 INVESTIGATING GENETIC VARIATION IN RHESUS MACAQUE INNATE 
IMMUNE GENES 
The innate immune system is now recognized as a factor that may exert a strong influence over 
the host response to infection and to vaccines.  In the current study, we are using the 
SIV:macaque model to explore the role of the innate immune system in inducing protective 
immunity.  CXCL13, CCL20, CCL1, CCL2, CCL5, and TRIM5α, molecules of the innate 
immune system, have been selected from a list of other innate immune genes to begin 
investigating the relationship between these molecules and vaccine response.  Although the 
rhesus macaque is a good model system in which to study vaccine response, little is known about 
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the extent of genetic variation in this species.  This contrasts strongly with the extensive data 
available on genetic variation in humans. We have begun to address this deficiency by 
resequencing many innate immune response genes in a cohort of rhesus macaques previously 
studied for two models of vaccine responsiveness. 
1. A model of mucosal viral challenge, in which animals were exposed mucosally to a low 
dose of SIV, followed later by a higher dose of virus.  In this study, animals were divided 
into those who were protected as a result of the earlier low-dose challenge, and those for 
whom this did not confer protection 
2. A vaccine model, using a particle-mediated (PMED) DNA vaccine.  In this study, 
animals who received the vaccine were divided into ones that were protected against 
subsequent high-dose challenge and those that were not protected.  This study also 
included a control group that did not receive a vaccine.  
This study of variation in rhesus macaque innate immune genes is the first of its kind.  
Hopefully, the characterization of genes in this study can lay the groundwork for future studies to 
further elucidate the relationship between variation in the innate immune system and immune 
response.  Understanding genetic factors that influence macaque responses to SIV vaccines will 
help us to better understand HIV in humans with the goal of developing a more effective vaccine 
and the ability to predict an individual’s susceptibility to disease or response to vaccination. 
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2.0  STUDY OVERVIEW 
2.1 HYPOTHESIS 
Very little is known about genetic variation in rhesus macaques, making this study of variation in 
macaque chemokine genes, the first of its kind. Thus, the primary goal of this study is to 
characterize genetic variation by resequencing many innate immune response genes in a cohort 
of rhesus macaques.  We hypothesize that variation in rhesus macaque chemokine genes 
influences protective immunity against SIV challenge. 
2.1.1 Specific Aim 1: Characterize genetic variation 
Characterize variation in rhesus macaque chemokine genes by identifying single nucleotide 
polymorphisms (SNPs) and determining copy number variation (CNV). Genomic DNA from 25 
rhesus macaques will be used to sequence genes of the innate immune system and identify 
polymorphisms which may control expression.  For these same genes, quantitative real time PCR 
will be used to determine CNV in the same cohort of 25 macaques. 
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2.1.2 Specific Aim 2: Determine relationship between genetic variation and protective 
immunity 
Determine association between variation in innate immune genes and vaccine response. The 
polymorphisms and copy number variation these innate immune genes will be analyzed in the 
cohort of 25 rhesus macaques that were part of a SIV vaccine trial, a multiple low dose exposure 
study, or a control group with the goal of determining the relationship between variation in these 
genes and protective immunity. 
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3.0  MATERIALS AND METHODS 
3.1 SAMPLES 
DNA obtained from venous blood drawn from 25 outbred Indian-origin rhesus macaques was 
provided by Dr. Murphey-Corb.  The macaques were part of a SIV vaccine trial (PMED), a 
multiple low dose exposure study (Mucosal), or a control group (Table 1).  This genomic DNA 
was initially used to make a working stock of DNA for each sample at a final concentration of 
5ng/μL.  Because genomic DNA for these samples was limited, whole genome amplification was 
performed, using the Illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare), to create a 
larger quantity of DNA for each animal.  Although this GenomiPhi DNA is reliable for 
sequencing and SNP detection, it is not ideal for use in CNV assays.  Thus, we obtained venous 
blood samples from 19 newly recruited Chinese-origin rhesus macaques (Table 2) from which 
genomic DNA was isolated.  This genomic DNA was used for CNV assays.  As these animals 
were newly recruited, their disease outcome is not yet available for analysis.   
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Table 1:  Original 25 Study Animals 
Study Group Animal # Code # Exposure Outcome Challenge Outcome 
PMED Vaccinates 8097 SIV04 NA Not protected 
  11797 SIV06 NA Not protected 
  11897 SIV03 NA Not protected 
  12097 SIV05 NA Protected 
  12297 SIV07 NA Protected 
  7697 SIV02 NA Protected 
  7797 SIV01 NA Protected 
 Controls 7097 SIV14 NA Infected 
  7297 SIV15 NA Infected 
  8497 SIV16 NA Infected 
  698 SIV08 NA Infected 
  1798 SIV09 NA Infected 
  2298 SIV10 NA Infected 
  1698 SIV11 NA Not Infected 
      Mucosal MAC239/Colonic N255 SIV17 Transient Not Protected 
  M224 SIV18 Infected Not Protected 
  M029 SIV19 Transient Not Protected 
  L870 SIV20 Transient Protected 
 17E-FR/Colonic N041 SIV13 Negative Protected 
  N385 SIV12 Infected Not Protected 
  N138 SIV21 Infected Not Protected 
  M155 SIV22 Uninfected Not Protected 
  L987 SIV23 Uninfected Not Protected 
  M259 SIV24 Infected Not Protected 
    M577 SIV25 Uninfected Protected 
Original study animals were a cohort of 25 Indian origin rhesus macaques that were either part of an SIV vaccine 
trial (16) or a multiple low dose exposure study (35) 
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Table 2: Newly Included 19 Study Animals 
Animal # Code # 
R0070 m01 
R0081 m02 
R0063 m03 
R0078 m04 
R0563 m05 
R0701 m06 
R0702 m07 
R0072 m08 
R0705 m09 
R0704 m10 
R0564 m11 
R0697 m12 
R0698 m13 
R0700 m14 
R0037 m15 
 m16 
R0024 m17 
R0074 m18 
R0069 m19 
Newly Included animals were a 
cohort of 19 Chinese origin rhesus 
macaques 
 
3.2 WHOLE GENOME AMPLIFICATION 
Because genomic DNA from the original 25 rhesus macaques samples was limited, a whole 
genome amplification was performed to create a substantial amount of DNA for each sample that 
could be used for PCR and sequencing.  The whole genome amplification was carried out using 
the general protocol that accompanied the Illustra GenomiPhi V2 DNA Amplification Kit (GE 
Healthcare).  For each sample, 9μL of sample buffer was combined with 1μL DNA (10ng) and 
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heated to 95°C for 3 minutes and then cooled to 4°C.  10μL of master mix (9μL of reaction 
buffer, 1μL enzyme mix) was added.  The tubes were then incubated at 30°C for 1.5 hours before 
the enzyme was inactivated by heating to 65°C for 10 minutes and then cooled to 4°C.  Gel 
electrophoresis was used to confirm the success of the amplification.  The samples were then 
diluted 1:100 for use in later PCR. 
3.3 POLYMERASE CHAIN REACTION (PCR) 
3.3.1 Primer Design 
The published rhesus macaque genomic sequence data was used to design PCR and sequencing 
primers for the CXCL13, CCL20, CCL1, CCL2, CCL5, and TRIM5α genes using Primer3 
software.  Each pair of primers was designed to yield a PCR product about 400-600 basepairs in 
length.  Enough primers were designed for each gene to cover all exons and about 2 kilobases of 
upstream promoter region.  PCR, sequencing, and SYBR green primers were ordered through 
Integrated DNA Technologies (IDT). 
3.3.2 PCR 
For each pair of primers, the optimal magnesium concentration and annealing temperature was 
determined by running a PCR with a temperature gradient and a magnesium titration.  First, 4 
PCR master mixes were made, each with a different magnesium concentration (1.0mM, 1.5mM, 
2.0mM, and 2.5mM) using AmpliTaq Gold reagents (Applied Biosystems) and dNTPs 
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(Invitrogen) (Table 3).  Each master mix was aliquoted into an 8-tube strip (Phenix) with the 
final volume in each tube being 25 μL.   
Table 3:  PCR Reagents 
 Final MgCl2 concentration in master mix 
 1.0mM  1.5mM  2.0mM  2.5mM  
Reagents Volume per reaction (μL) 
DNA (5ng/μL) 2.0 2.0 2.0 2.0 
10X PCR Buffer 2.5 2.5 2.5 2.5 
MgCl2 (25mM) 1.0 1.5 2.0 2.5 
dNTPs (25mM) 0.2 0.2 0.2 0.2 
Primers (10mM) 0.4 0.4 0.4 0.4 
AmpliTaq Gold 0.2 0.2 0.2 0.2 
Sterile Distilled Water 18.7 18.2 17.7 17.2 
Total Volume (μL) 25.0 25.0 25.0 25.0 
 
The four 8-tube strips were put into an Eppendorf Mastercycler and a temperature gradient cycle 
(Table 4) was run so that each tube in an 8-tube strip was run with a different annealing 
temperature.  The annealing temperatures ranged from 52°C to 62°C.   
Table 4:  PCR Gradient Program 
Step Temperature (°C) Time 
1 94 2 min 
2 94 30 sec 
3 52 15 sec 
annealing temperature gradient of 10°C 
4 72 30 sec 
steps 2-4, repeat 34 times 
 
Gel electrophoresis was then used to separate the DNA in the PCR products.  After UV light was 
used to visualize the products, optimal PCR conditions were determined by assessing at which 
magnesium concentration and annealing temperature the cleanest and brightest bands were 
produced.  The optimized PCR conditions were used to amplify DNA in 24 of the 25 macaque 
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DNA samples with each pair of primers.  Twenty-four (instead of all 25) samples were used 
because 24 is divisible by 8, making it far more convenient for amplification in 8-tube strips and 
96-well plates.  After each PCR, gel electrophoresis was used to confirm the presence of 
amplified DNA. 
3.4 GEL ELECTROPHORESIS 
PCR products were run on a 2% agarose gel, which was made by combining 4g of GenePure LE 
agarose powder (ISC BioExpress) in 200mLs of 0.5X TBE (ISC BioExpress) buffer and heating 
in a microwave until all agarose was dissolved.  Once removed from the microwave, 10μL 
ethidium bromide was added to the agarose mixture.  The liquid mixture was poured into a form, 
combs were inserted, and it was allowed to cool and set.  5μL of the PCR product was combined 
with 5μL 6X loading dye and loaded into the gel, along with one well of a ladder, Phi-X174 RF 
DNA Hae III digest (Thermo Scientific).  The loaded gel was run at 100V for 30 minutes in a 
running buffer of 300mL 0.5X TBE buffer and 15μL ethidium bromide.  After the gel was run, it 
was taken to a gel documentation system and the ethidium bromide-stained DNA was visualized 
using UV light. 
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3.5 SANGER SEQUENCING 
3.5.1 ExoSAP 
After PCR was confirmed to have worked via gel electrophoresis, 10μL of the remaining PCR 
product was used for sequencing.  First, an ExoSAP reaction was run, using an Exonuclease 
enzyme (NewEngland BioLabs) and an alkaline phosphatase (Roche), to remove any 
unconsumed dNTPs and primers, which could interfere with the sequencing reaction.  For this 
reaction, a master mix was created with the ExoSAP reagents.  For each amplified sample, 10μL 
of PCR product was pipetted into a well of a 96-well 0.2mL, low profile PCR plate (ISC 
BioExpress).  10μL of ExoSAP master mix was added to each well with a repeat dispenser.  The 
plate was loaded into an Eppendorf Mastercycler and the ExoSAP program was run.   
Table 5:  ExoSAP Reagents 
Reagents Volume per reaction (μL) 
Exonuclease I 0.05 
rAPid Alkaline Phosphatase 1.0 
rAPid Alkaline Phosphatase buffer (10X) 1.0 
Sterile Distilled Water 7.95 
Total Volume (μL) 10.0 
 
Table 6:  ExoSAP Program 
Step Temperature (°C) Time 
1 37 60 min 
2 85 15 min 
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3.5.2 BigDye 
After the ExoSAP reaction was complete, the clean PCR products were transferred to clean 
semi-skirted optical 96-well plates (Applied Biosystems) using an 8-channel pipette.  From each 
row of PCR products in the ExoSAP plate, 5μL were pipetted into 2 different rows in the clean 
plates such that every clean PCR product was represented twice in order to run both a forward 
and reverse sequencing reaction.  A BigDye master mix was created for each individual primer 
using the BigDye reagents (Applied Biosystems) and a 1:500 dilution of the primer from the 
original stock, giving a final primer concentration of 10mM.  5μL of the master mix was added 
to the 5μL PCR product.  The plates were loaded into the Eppendorf Mastercyclers and the 
sequencing reaction was run. 
Table 7:  BigDye Reagents 
Reagents Volume per reaction (μL) 
Primers (10mM) 2.5 
5X Dilution Buffer 2.0 
BigDye Terminator 0.5 
Total volume (μL) 5.0 
 
Table 8:  BigDye Program 
Step 
Temperature 
(°C) Time 
1 96 2 min 
2 96 10 sec 
3 50 5 sec 
4 60 4 min 
steps 2-4, repeat 24 times 
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3.5.3 Ethanol/EDTA precipitation 
After the BigDye reaction was complete, each 10μL sequencing reaction product was transferred 
to a clean 96-well optical plate using an 8-channel pipette.  To each well 5μL of 125mM 
ethylenediaminetetraacetic acid (EDTA) and 60μL 100% ethanol were added.  The plate was 
sealed and inverted 4 times before incubation at room temperate for 15 minutes in a dark lab 
drawer, as the BigDye reagents can be degraded by light.  Plates were loaded into the centrifuge 
and spun at 2500 x g for 30 minutes at 4°C.  The supernatant was then removed by inverting the 
plate over the sink and using a flick of the wrist.  60μL of 70% ethanol was then added to each 
well.  The plates were again sealed and spun at 1650 x g for 15 minutes at 4°C.  The supernatant 
was again removed, and the plates were inverted onto a stack of about 5 paper towels and spun in 
the centrifuge for a few seconds.  The plates were then allowed to air dry for about 20 minutes in 
a dark lab drawer.  They were then sealed and sent to the University of Pittsburgh Genomics and 
Proteomics Core Laboratories facility (GPCL) for capillary electrophoresis. 
3.6 SNP DETECTION 
To analyze the DNA for polymorphisms, the sequencing data from GPCL was imported into 
Sequencher software along with the published rhesus macaque reference sequence for each gene.  
Sequencing data for each gene was organized into its own contiguous assembly with the 
appropriate reference sequence.  The software aligns all of the forward and reverse reads from 
each sample with the reference sequence and highlights any ambiguities.  Each ambiguity was 
then visually analyzed to determine if it was the result of a genuine SNP, messy sequencing data, 
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or poor call made by the software.  For each SNP, the allele frequencies were compared between 
the different exposure groups using a t-test for proportions. 
3.7 STR GENOTYPING 
At the end of the CXCL13 gene there is a Short Tandem Repeat (STR).  In order to characterize 
this variant region, genotyping was used.  Primers were designed, as described previously, to 
amplify the STR region at the end of the gene.  These primers, however, were fluorescently 
labeled with FAM.  PCR was run as described previously, and the PCR products were sent to 
GPCL in an optical 96-well plate for capillary electrophoresis. 
3.8 COPY NUMBER VARIATION ANALYSIS 
3.8.1 TaqMan method 
Fluorescently-labeled custom TaqMan primers and probes were designed using the Primer3 
software program for CXCL13 and a control gene STAT6, which is known to be present at 2 
copies per diploid cell.  Custom probes have to be designed because Applied Biosystems does 
not sell ready-made assays for the rhesus macaque, only for human and mouse.  To optimize the 
assay, a standard curve was first prepared, where STAT6 was present at 300,000 copies, 30,000 
copies, 3,000 copies, 300 copies, and 30 copies.  To do this, the calculations in the Applied 
Biosystems worksheet, Creating Standard Curves with Genomic DNA or Plasmid DNA 
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Templates for Use in Quantitative PCR, were followed.  Using these calculations, 5 dilutions of 
DNA were made from the same DNA sample.  A master mix was created for each gene, using 
Sso Fast reagents (BioRad) and the custom TaqMan probes (Applied Biosystems), and 10μL of 
this master mix was added to 5μL DNA in a semi-skirted, green 96-well plate (Eppendorf).   
Table 9:  TaqMan Assay Reagents 
Reagents Volume per reaction (μL) 
SsoFast Probes Supermix 7.5 
20X probe 0.375 
Sterile Distilled Water 2.125 
Total Volume (μL) 10 
 
The plate was loaded into an Eppendorf realplex4 Mastercycler.  Each DNA dilution was run in 
triplicate for both STAT6 and CXCL13.  After the PCR program was run, the efficiencies of the 
probes were assessed and the magnesium concentration was increased in future runs for CXCL13 
in order to bring its efficiency closer to that of STAT6.  Once the assay was optimized, it was run 
again using 16 genomic macaque DNA samples diluted to 19.8ng/μL.  Each sample was run in at 
least triplicate for each gene.  The results were analyzed using CopyCaller software (Applied 
Biosystems). 
3.8.2 SYBR Green method 
The SYBR Green method was used to analyze CNV for the rest of the genes, because custom 
TaqMan probes were both expensive and took weeks for the company to synthesize.  The SYBR 
Green method uses non-fluorescently labeled primers that are inexpensive and quick to 
synthesize.  The DNA is amplified with these primers in the presence of SYBR Green dye, a 
fluorescent dye that non-specifically binds double stranded DNA.  First, primers were designed, 
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as described previously, for CXCL13, CCL1, STAT6 (control gene, present at 2 copies per diploid 
genome), and CCL3L (known to show copy number in rhesus macaques).  It is important that the 
primers for each gene are designed such that the amplified product from each gene is the same 
size so that the amount of fluorescence is comparable between genes.  For the SYBR green 
assay, 8μL of master mix, created using SYBR Green reagents (Qiagen), was added to 2μL of 
DNA in a semi-skirted, green 96-well plate (Eppendorf).   
Table 10:  SYBR Green Assay Reagents 
Reagents Volume per reaction (μL) 
SYBR Green ROX qPCR MasterMix 5.0 
Primers 0.2 
DNA (5ng/μL) 2.0 
Sterile Distilled Water 2.8 
Total Volume (μL) 10.0 
 
The same 16 genomic macaque DNA samples that were used in the TaqMan method were used 
in the SYBR green assay, except they were diluted to 5ng/μL.  Each sample was run in triplicate 
for each gene. 
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4.0  RESULTS 
4.1 AIM 1: CHARACTERIZE GENETIC VARIATION IN RHESUS MACAQUE 
INNATE IMMUNE GENES 
4.1.1 SNP detection 
4.1.1.1 CXCL13 
The CXCL13 chemokine, also referred to as B lymphocyte chemoattractant (BLC) or B cell-
attracting chemokine 1 (BCA-1), is highly chemotactic for B-cells.  It is important for proper B-
cell trafficking and germinal center formation(2, 30).  Although it is known that CXCL13 is 
important for B-cell homing and antibody production, its role in SIV pathogenesis is less clear.  
CXCL13 is upregulated during infection, and may play a role in trafficking other cell types, such 
as dendritic cells and follicular helper T cells, to the germinal center(39).   
Seven different PCR amplicons were used to examine variation in the exons and 
promoter region of CXCL13.  Twenty-nine SNPs were detected in CXCL13 (Figure 1, Table 11).  
No SNPs were found in the amplicon containing exons 3 and 4.  Overall, 15 SNPs were detected 
in the promoter region and 2 synonymous SNPs were detected in exons (Table 18).  The 
available genome sequence of CXCL13 contains a gap of 851bp, which we have sequenced and 
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will be depositing on Genbank. Genotyping of the STR, CTTn, at the end of the gene revealed 
that the number of repeats is highly variable among animals.   
 
 
Table 11:  CXCL13 SNPs 
SNP # animals sequenced allele frequency 
A-2012C 22 1 
T-1921C 22 0.55 
G-1797A 20 0.4 
C-1758T 20 0.53 
G-1671A 17 0.06 
G-1607A 17 0.53 
C-1521T 16 0.44 
A-1421T 25 0.52 
G-1308G 25 0.5 
G-1251A 25 0.54 
G-1208T 25 0.52 
G-1176A 25 0.54 
G-1132C 25 0.96 
G-1060T 24 0.44 
C-993T 24 0.02 
C-956T 24 0.81 
ins-932G 20 0.15 
G-684A 25 0.56 
G-476C 24 0.42 
G-432A 24 0.6 
G15A 25 0.62 
C200T 24 0.58 
C302T 24 0.4 
C1780A 18 0.47 
G1949A 20 0.55 
Figure 1:  Rhesus macaque CXCL13 gene 
Exons are shown on the scale line.  PCR amplicons generated for sequencing are shown above the 
line, and SNPs discovered are shown as tick marks below the gene.  The blue box below the line 
denotes the CTT STR region. 
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C2213T 12 0.54 
G6012A 8 0.06 
C6232T 8 0.13 
C6330T 10 0.9 
 
4.1.1.2 CCL20 
CCL20 is also known as liver and activation-regulated chemokine (LARC), macrophage 
inflammatory protein-3α (MIP-3α), and Exodus(49).  This chemokine is expressed in the liver 
and mucosal tissue(20) and is chemotactic for immature dendritic cells and T lymphocytes, 
subsets of which express the CCL20 receptor, CCR6(4, 49).  The primary role of CCL20 is the 
trafficking of lymphocytes and immature dendritic cells to sites in mucosal tissue(10, 11, 55).  
During pathogenic SIV infection of non-natural hosts, CCL20 is upregulated in lymph nodes(38). 
Seven different amplicons were designed to examine variation in the promoter and exons 
of CCL20.   Eighteen SNPs were detected in CCL20 (Figure 2, Table 12).  Eight of these SNPs 
were found in the promoter and 1 nonsynonymous SNP was detected in an exon (4.1.1.7).  No 
SNPs were found in the amplicon containing exon 4.   
 
 
 
Figure 2:  Rhesus macaque CCL20 gene 
Exons are shown on the scale line.  PCR amplicons generated for sequencing are shown above the 
line, and SNPs discovered are shown as tick marks below the gene.  The blue box below the line 
denotes a repeat region identified by the RepeatMasker software. 
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Table 12:  CCL20 SNPs 
SNP # animals sequenced allele frequency 
G-1181C 23 0.33 
G-1123A 22 0.3 
G-1034C 25 0.04 
A-930C 25 0.02 
C-639T 24 0.06 
T-595C 24 0.44 
T-448C 25 0.02 
A-398G 24 0.42 
G-326T 25 0.04 
A-251G 25 0.02 
G-193T 19 0.21 
G-179T 25 0.02 
ins-46G 21 0.88 
G36T 23 0.11 
A191G 22 0.3 
A1491G 22 0.55 
A2333G 19 0.08 
A2489G 16 0.09 
 
 
4.1.1.3 CCL1 
CCL1, or human cytokine I-309, is secreted by activated T cells(31).  It is chemotactic for 
monocytes(31), which express the receptor CCR8(43). 
Originally, 3 amplicons were designed to examine variation in the promoter region and 2 
exons.  Ten SNPs were detected in CCL1 (Figure 3, Table 13).  Two of these SNPs were found 
to be nonsynonymous SNPs in exons (4.1.1.7).  The available genome sequence of CCL1 
contains a gap of about 3000bp, which we are currently sequencing and will deposit on Genbank.  
As sequencing data for this region becomes available, more SNPs are likely to be found. 
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Table 13:  CCL1 SNPs 
SNP # animals sequenced allele frequency 
C-45T 23 0.04 
T98C 23 0.89 
T131G 22 0.16 
C257T 23 0.07 
C366G 22 0.02 
T1238C 20 0.1 
G1280A 23 0.24 
C1320T 23 0.07 
A1501G 23 0.87 
C1576T 23 0.65 
 
4.1.1.4 CCL2 
CCL2, also known by other names including monocyte chemoattractant protein-1 (MCP-1), is 
chemotactic for monocytes, T cells, and NK cells(8, 19).  The receptor for this chemokine is 
CCR2(27). 
Six amplicons were used to examine variation in the promoter region and exons of CCL2.  
Seventeen SNPs were detected in CCL2 (Figure 4, Table 14), all in the promoter and introns 
(Table 18). 
 
Figure 3:  Rhesus macaque CCL1 gene 
Exons are shown on the scale line.  PCR amplicons generated for sequencing are shown above 
the line, and SNPs discovered are shown as tick marks below the gene.  Blue boxes below the 
line denote repeat regions identified by the RepeatMasker software. 
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Table 14:  CCL2 SNPs 
SNP # animals sequenced allele frequency 
A-1925G 23 0.93 
T-1581C 24 0.6 
C-1558T 24 0.58 
T-1530C 24 0.04 
C-1032T 24 0.04 
C-878T 24 0.02 
G-874T 24 0.54 
C-850T 24 0.04 
G-578A 24 0.6 
G-495C 24 0.6 
G-430A 24 0.1 
T-79C 23 0.61 
G-33T 20 0.63 
C711A 24 0.29 
C971T 24 0.29 
C1459T 24 0.31 
A1550C 23 0.3 
 
4.1.1.5 CCL5 
CCL5 is also known as RANTES (regulated upon activation, normal T cell expressed and 
secreted).  As its name suggests, this chemokine is expressed by T cells and is also chemotactic 
for T cells, eosinophils, and basophils(12, 44, 47).  During pathogenic SIV infection of non-
natural hosts, CCL5 is upregulated in lymph nodes as well as in the intestinal tissue(39). 
Figure 4:  Rhesus macaque CCL2 gene 
Exons are shown on the scale line.  PCR amplicons generated for sequencing are shown above 
the line, and SNPs discovered are shown as tick marks below the gene.   
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Six amplicons were designed to examine variation in the promoter region and exons of 
CCL5.  Seven SNPs were detected in CCL5 (Figure 5, Table 15), all in the promoter and introns 
(Table 18). 
 
 
 
 
Table 15:  CCL5 SNPs 
SNP # animals sequenced allele frequency 
C-1142T 23 0.26 
G-1141A 23 0.3 
A-339G 22 0.91 
A-135G 24 0.81 
C113T 23 0.28 
G8000T 21 0.55 
T8309A 23 0.04 
 
 
4.1.1.6 TRIM5α 
TRIM5α (tripartite motif-5alpha) is a cellular restriction factor.  This factor is found in most 
primates and is considered to be an important innate immune defense against retroviruses.  
TRIM5α demonstrates species-specific restriction.  In other words, TRIM5α of different primate 
Figure 5:  Rhesus macaque CCL5 gene 
Exons are shown on the scale line.  PCR amplicons generated for sequencing are shown above the 
line, and SNPs discovered are shown as tick marks below the gene.  Blue boxes below the line 
denote repeat regions identified by the RepeatMasker software. 
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species prevents infection by different retroviruses.  Human TRIM5α is able to restrict 
retroviruses that infect other species.  TRIM5α of African monkeys is able to prevent infection by 
HIV-1, but human TRIM5α is not(1, 3, 26, 41, 54, 58).  The difference between TRIM5α that can 
restrict HIV-1 and TRIM5α that cannot is a single amino acid at position 332.  In humans, this 
amino acid position is filled by an arginine while in monkeys it is a proline(58).  Although the 
exact mechanism is unknown, TRIM5α is thought to act by interacting with and degrading capsid 
proteins, inhibiting viral replication(1, 3, 26, 41, 54, 58).   
Seven PCR amplicons were designed to examine variation in the exons and untranslated 
regions of TRIM5α.   Forty-eight SNPs were detected in TRIM5α (Figure 6, Table 16). 
 
Table 16:  TRIM5α SNPs 
SNP # animals sequenced allele frequency 
G-11T 23 0.98 
G42C 23 0.46 
A9340C 8 0.25 
C9433T 19 0.13 
A9491T 13 0.38 
G9834A 22 0.18 
T10162C 22 0.66 
T10479C 22 0.48 
G10679T 22 0.27 
C10686T 22 0.5 
Figure 6:  Rhesus macaque TRIM5α gene 
Exons are shown on the scale line in red.  5’ and 3’ untranslated regions are shown on the scale line in white.  
PCR amplicons generated for sequencing are shown above the line, and SNPs discovered are shown as tick 
marks below the gene.  Blue boxes below the line denote repeat regions identified by the RepeatMasker 
software. 
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A10687G 22 0.5 
C11215T 22 0.5 
C11219T 22 0.18 
C11233T 22 0.48 
G11252T 22 0.45 
T11324C 13 0.04 
C11338A 14 0.04 
C11343T 13 0.12 
C11350T 13 0.54 
T11378C 13 0.12 
C11437T 13 0.12 
G11443A 13 0.12 
G11456A 13 0.12 
A11480G 21 0.26 
A11500T 21 0.48 
C23693T 22 0.02 
G23737A 21 0.21 
G25393A 16 0.5 
A25478G 17 0.47 
C25527T 17 0.65 
T25651C 19 0.18 
G25667T 19 0.18 
C25680T 19 0.18 
A25689G 19 0.18 
C25722T 20 0.18 
A25770G 22 0.23 
A25823C 22 0.2 
C25916T 22 0.18 
C25973A 22 0.18 
G25987A 22 0.18 
C25992T 22 0.21 
C26033A 14 0.21 
A26049G 12 0.02 
A26094T 8 0.06 
G26140A 8 0.06 
T26207C 8 0.06 
A26275G 8 0.44 
T26319C 8 0.5 
 
Although many TRIM5α alleles exist, they can be classified into 3 allelic classes (TFP, Q, CypA) 
based on variation in the C-terminal domain(42).  These alleles demonstrate different restrictive 
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capabilities against different strains of SIV in macaques.  The TFP/CypA genotype tends to be 
most restrictive, while the Q/Q genotype tends to be the least restrictive.  Thus, animals with 
Q/Q tend to demonstrate poor virus control(25, 42).  The TFP and Q allele types are 
differentiated by the presence of a 6 base pair insertion or deletion at positions 1015-1020 
(amino acids 339-340).  The TFP allele contains the 6 base pair insertion, and as a result, that 
region encodes threonine, phenylalanine, and proline.  The Q allele, however, lacks this 6 base 
pair insertion and instead encodes a glutamine(25, 35).  The CypA allele type is unique in that it 
is a splicing mutation that results in part of the TRIM5 C-terminal domain to be replaced by part 
of the cyclophilin A gene, resulting in a TRIM5-cyclophilin A chimeric protein.  The mutation 
responsible for this alternative splicing is a G/T SNP in last position of intron 6.  A guanine at 
this position results in wildtype TRIM5α, either a TFP or a Q allele.  A threonine at this position, 
however, results in alternative splicing where exons 7 and 8 are replaced by a cyclophilin A-
pseudogene that has been retrotransposed into the 3’UTR of the TRIM5α gene(36).  This 
chimeric protein is still functional because cyclophilin A is also a capsid-binding protein(45). 
 The TRIM5α sequencing data that was used to detect SNPs was also used to categorize 
the TRIM5α of each monkey into the 3 allelic classes.  First, the sequences were examined for 
the 6 base pair insertion/deletion to differentiate between TFP and Q alleles.  The sequences 
were also examined for the G/T SNP at the end of intron 6 to determine the presence or absence 
of the CypA allele.  The 6 base pair insertion/deletion and the G/T SNP were used to determine 
the TRIM5α genotype in the original cohort of monkeys (Table 17). Individuals that were 
heterozygous for cypA could not be fully typed because it is difficult to determine which allele 
contains the mutation using genomic DNA alone.  Interestingly, the CypA mutation was found 
on both TFP and Q allelic backgrounds.  The TRIM5α genotype, however, did not appear to 
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relate to disease outcome in this cohort of rhesus macaques.  Other factors may influence this 
relationship, including the strains of virus used, the titer of inocula, and other host genetic 
factors. 
Table 17:  TRIM5α allelic classes 
monkey study outcome 339-340 cypA 
SIV01 PMED protected TFP/Q wildtype/wildtype 
SIV02 PMED protected - - 
SIV03 PMED not protected TFP/Q wildtype/wildtype 
SIV04 PMED not protected TFP/Q wildtype/wildtype 
SIV05 PMED protected TFP/Q cypA/cypA 
SIV06 PMED not protected - wildtype/wildtype 
SIV07 PMED protected TFP/Q wildtype/wildtype 
SIV08 PMED infected - - 
SIV09 PMED infected TFP/Q wildtype/wildtype 
SIV10 PMED infected Q/Q wildtype/wildtype 
SIV11 PMED not infected Q/Q - 
SIV12 MUCOSAL not protected TFP/Q wildtype/wildtype 
SIV13 MUCOSAL protected TFP/Q cypA/wildtype 
SIV14 PMED infected TFP/Q - 
SIV15 PMED infected TFP/Q cypA/wildtype 
SIV16 PMED infected TFP/Q cypA/wildtype 
SIV17 MUCOSAL not protected TFP/TFP wildtype/wildtype 
SIV18 MUCOSAL not protected TFP/Q cypA/cypA 
SIV19 MUCOSAL not protected TFP/Q wildtype/wildtype 
SIV20 MUCOSAL protected Q/Q wildtype/wildtype 
SIV21 MUCOSAL not protected TFP/Q - 
SIV22 MUCOSAL not protected - wildtype/wildtype 
SIV23 MUCOSAL not protected TFP/Q wildtype/wildtype 
SIV24 MUCOSAL not protected TFP/TFP wildtype/wildtype 
SIV25 MUCOSAL protected Q/Q cypA/cypA 
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4.1.1.7 Amino Acid Changes 
If a SNP falls within an exon of a gene, it could result in an amino acid change, potentially 
altering the function of the protein.  Of the 81 SNPs detected in the 5 chemokine genes, 5 were 
found in exons.  Two of these SNPs were synonymous, while the other 3 were predicted to result 
in an amino acid change.  The 2 exonic SNPs in CXCL13 were not predicted to change the amino 
acid at those positions.  In both cases, a serine would remain a serine.  For CCL20, the exonic 
SNP is predicted to change a leucine to a phenylalanine.  Lastly, the two exonic SNPs in CCL1 
are predicted to change a tyrosine to histidine and a leucine to a phenylalanine (Table 18).   
 
Table 18:  Chemokine SNP summary 
Gene  SNPs    
 Total Promoter Introns Exons Amino Acid 
CXCL13  29 15 12 2 S→S, S→S 
CCL20  18 8 9 1 L→F 
CCL1  10 1 7 2 Y→H, L→F  
CCL2  17 13 4 0  
CCL5  7 4 3 0  
 
4.1.2 CNV 
Because copy number assays yield more reliable results with the use of genomic DNA, 
compared to whole genome amplified DNA, all CNV assays were performed using genomic 
DNA isolated from 19 PBMC samples.  These 19 rhesus macaques were only recently included, 
thus their disease outcome is not yet available for analysis.  First, custom TaqMan probes and 
quantitative real time PCR were used to determine copy number variation (CNV) in CXCL13 
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(Figure 7).  Analysis of this PCR using CopyCaller software revealed that this innate immune 
gene does show copy number variation (Figure 8).   
 
 
Figure 7:  CNV Quantitative Real-Time PCR  
PCR curves of 16 genomic DNA samples in triplicate using custom TaqMan Copy 
Number Probes for CXCL13 (top panels) and a control gene, STAT6 (bottom panels). A: 
CXCL13, monkeys 01-08; B: CXCL13, monkeys 09-16; C: STAT6, monkeys 01-08; D: 
STAT6, monkeys 09-16. 
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Figure 8:  CXCL13 Copy Number Variation 
Copy Number Variation (CNV) was examined in 16 genomic DNA samples using 
custom TaqMan Copy Number probes for CXCL13.  STAT6 was used as a control gene 
(present at 2 copies per diploid genome). 
 
Although the TaqMan assay seemed to work well, it did have its drawbacks including the 
lengthy amount of time for probes to be synthesized and the high cost of the reagents.  Thus, we 
decided to use SYBR Green to analyze CNV in the remaining genes, as well as to replicate the 
results from the TaqMan assay for CXCL13.  CCL3L was also included because it is known to 
show CNV in rhesus macaques, and could serve as a kind of positive control to demonstrate that 
the SYBR Green assay was working.  Initially, the SYBR Green assay was performed using 
primers for CXCL13, CCL1, CCL3L, and STAT6 (control gene, shown to be present at 2 copies 
per diploid genome).  Although the PCR worked well and was consistent, analysis revealed no 
copy number variation in any of the genes, including CXCL13 which was believed to show CNV 
based on the TaqMan assay, and CCL3L which is known to be highly variable among 
individuals. 
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4.2 AIM 2:  DETERMINE THE RELATIONSHIP BETWEEN VARIATION IN 
INNATE IMMUNE GENES AND VACCINE RESPONSE 
4.2.1 SNPs 
Numerous SNPs were detected in all of the innate immune genes studied.  None of the SNPs 
identified showed significant difference in frequency between the responder and non-responder 
groups, based on a t-test of proportions. It is important to note, however, that the small sample 
sizes of each group mean that these tests do not have adequate statistical power to detect 
anything other than extreme effect sizes.  A larger study would yield more definitive results.  
However, a study such as the current one, that characterizes variation in these innate immune 
genes, is necessary to lay the groundwork for larger studies.   
4.2.2 CNV 
Copy number variation was examined in these innate immune genes by two different methods.  
Because the TaqMan assay and analysis software are specifically designed to detect CNV, it is 
likely the more reliable of the two methods.  Thus, CXCL13 most likely shows copy number 
variation.  As the genomic DNA from the 19 newly recruited animals was used for the CNV 
assays, statistical analysis cannot be conducted because the disease outcome data are not yet 
available for these animals. 
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5.0  DISCUSSION 
5.1 OVERVIEW OF CURRENT STUDY 
Very little is known about genetic variation in rhesus macaques, making this study of variation in 
macaque chemokine genes, the first of its kind. Thus, the primary goal of this study was to 
characterize genetic variation in rhesus macaque innate immune response genes.  The immune 
system is comprised of a vast number of proteins that could play a role in SIV vaccine responses 
and disease outcomes.  To focus the study, a list of genes with clear antimicrobial and/or 
chemotactic activities or a role in inflammation was made.  One by one, genes were selected 
from this list and examined for variation.  We hypothesized that variation in rhesus macaque 
innate immune genes influences protective immunity against SIV challenge. 
5.2 SNP DETECTION 
Although numerous SNPs were detected in all of the innate immune genes studied, none of them 
correlated with disease outcome in the cohort of 25 rhesus macaques available for this study.  A 
sample size of 25 animals is, however, quite small to detect the impact of genetic variation that 
does not have a profound effect on disease outcome.  The experimental design of the current 
study, however, was appropriate for characterizing previously undiscovered genetic variation in 
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rhesus macaques.  Thus, the SNPs detected in this study provide the basis for future studies that 
may examine their effects on protective immunity in greater detail.   
SNPs in innate immune genes have previously been shown to be associated with response 
to vaccines.  In a study of a DC based HIV-1 immuno-treatment, most people demonstrated an 
induction of HIV specific cellular immunity while a small portion of study participants did 
not(50).  The researchers found that two SNPs are significantly associated with response to this 
DC-based vaccine.  One SNP is located in the NOS1 gene which is involved in the production of 
nitric oxide, a pro-inflammatory and antimicrobial molecule of the innate immune system.  The 
second of the two SNPs is located in the MBL2 (mannose-binding lectin) gene, involved in the 
activation of the complement system(50).  Similarly, a SNP in another innate immune gene was 
found to be associated with response to the hepatitis B vaccine.  Although HLA (human 
leukocyte antigen) plays a role, a SNP in the FOXP1 gene, encoding a transcription factor that is 
involved in B-cell development, also influences vaccine response(13). 
It is usually not the case that one SNP in one gene results in a profound effect on disease 
outcome or vaccine response.  More often, disease outcomes are influenced by the cumulative 
effect of variation in several different genes(9, 37, 54).  It is likely that the SNPs characterized in 
this study do not have a profound effect on SIV vaccine response or disease outcome, but any 
given SNP may play a minor role and be part of the larger picture.  Even if the SNPs 
characterized in this study have no effect on the outcome of SIV challenge, they may play a role 
in the outcome of other diseases.    
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5.3 COPY NUMBER VARIATION 
Copy number variation was detected in CXCL13 using the TaqMan method (Figure 8).  Because 
CXCL13 is a gene of the immune system, this finding was not surprising.  Segmental 
duplications that can lead to copy number variation do not occur randomly throughout the 
genome.  Genes involved in immunity and defense, drug detoxification, and growth and 
development are particularly subject to these segmental duplications and thus often show copy 
number variation(5).   
Although CNV was detected in CXCL13, the impact of copy number in this gene on 
disease outcome is not able to be determined at this time.  Because a substantial volume of 
genomic DNA was needed for the CNV assays, DNA from 19 newly recruited animals was used.  
The disease outcome data are not yet available for these animals, putting statistical analysis on 
hold.  Copy number variation in other innate immune genes has previously been shown to be 
associated with the outcome of HIV-1 or SIV exposure.  In humans, more copies of CCL3L, 
relative to the geographical ancestry, is associated with lower susceptibility to HIV-1 infection 
and a slower progression to AIDS(18).  Similarly, in rhesus macaques infected with SIV, a lower 
number of copies of CCL3L is associated with more rapid progression to disease(14).  Thus, it is 
possible that CNV in CXCL13 plays a role in vaccine response and/or disease outcome.  Again, 
the role of this copy number on disease outcome may not be able to be revealed with such a 
small sample size.  Additionally, CNV in this gene may only be part of the puzzle, and may play 
a minor role on its own. 
Although CNV was detected in CXCL13 using the TaqMan method, these results were 
not supported by the SYBR Green method.  According to the results of the SYBR Green assay, 
none of the genes tested demonstrated copy number variation, including CCL3L which is known 
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to be highly variable in copy number among individuals(14, 29).  These results may be a 
function of the SYBR Green technology itself.  Compared to TaqMan assays, SYBR Green 
assays have lower specificity, and are not as sensitive.  Additionally, TaqMan assays can be 
specifically designed for detection of copy number of a gene, and the results can be analyzed 
using software designed to interpret results of TaqMan assays and detect copy number.  Thus, 
the results of the TaqMan assay are likely more reliable and if so, then CXCL13 does show copy 
number variation. 
5.4 FUTURE DIRECTIONS 
It is important to recognize that the main focus of this study was to characterize genetic variation 
in a small cohort of rhesus macaques.  Because little research has been dedicated to this topic in 
the past, this study was starting from square one.  Thus, to begin such an endeavor, it seemed 
logical to begin by resequencing genes of the innate immune system to detect and curate 
polymorphisms in these genes.  It is unlikely that the impact of such variation on protective 
immunity could be fully elucidated with such a small cohort of animals.  That subject can be 
addressed in future studies, for which this study lays the groundwork.  Specifically, this study 
has developed a list of novel candidate SNPs that can be applied to other studies.  SNPs of 
interest could be rapidly screened in a large group of samples, from both previous and current 
studies, using a TaqMan SNP genotyping assay. 
In addition to the innate immune genes examined in this study, it would beneficial to 
study other cellular restriction factors such as APOBEC3G and Tetherin.  APOBEC3G 
(apolipoprotein beta mRNA-editing enzyme catabolic polypeptide 1-like protein 3G) is a cellular 
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deaminase that gets packaged in newly formed virions, and helps to block viral replication.  
After entry of the virion, during reverse transcription, APOBEC3G works by deaminating 
cytosines to uridines in the negative DNA strand.  During positive strand synthesis, this 
deamination results in a guanine to adenine mutation.  The accumulation of such mutations can 
lead to DNA breakage or result in the introduction of premature stop codons(1, 3, 26, 28, 41, 48, 
52, 54, 58).  The HIV-1 Vif protein, however, counteracts the effects of APOBEC3G by marking 
it for degradation via polyubiquitination(58).  Tetherin is yet another cellular restriction factor 
that works by inhibiting the release of newly formed virions from the plasma membrane of the 
infected cell(3, 17).  Similar to the scenario with APOBEC3G, HIV-1 encodes a protein, in this 
case Vpu, that counters the effects of tetherin(17).   
5.5 PUBLIC HEALTH IMPLICATIONS 
Rhesus macaques provide a valuable model that have been used in numerous studies and have 
greatly advanced our understanding of HIV and AIDS, which remains a major public health 
problem.  Understanding genetic factors that influence macaque response to vaccine or SIV 
challenge will help us to better understand HIV in humans with the goal of developing a more 
effective vaccine and the ability to predict individual’s susceptibility to disease or response to 
vaccine. 
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APPENDIX A 
PCR PRIMERS AND PROBES 
Table 19:  CNV Primers and Probes 
Gene Source Primer Sequence Length/bp 
Stat6 Degenhardt et al., 2009 Forward CCAGATGCCTACCATGGTGC 129 
    Reverse CCATCTGCACAGACCACTCC   
    Probe CTGATTCCTCCATGAGCATGCAGCTT   
CCL3L Degenhardt et al., 2009 Forward CCAGTGCTTAACCTTCCTCC 122 
    Reverse TCAGGCACTCAGCTCCAGGT   
    Probe AGGCCGGCAGGTCTGTGCTGACC   
CXCL13 This study Forward GAGTCTGGAAGAAGAACAAGTCAGT 104 
    Reverse CCCCTTGTTATGCCTGACTTACTTT   
    Probe ACCCTCAAGCTGAATGGATACAG   
CCL1 This study Forward TTCTAAACCCAGAGTTGCCAGC 100 
    Reverse GCACAGATGCGTCCTTCCTTAC   
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Table 20:  PCR primers 
Gene Amplicon Forward Reverse Length/bp 
CCL1 Exon 1 GGTGAAGGCACATCTTCCTCAAG TTGGCACCTTGGAGTTTCAGG 608 
CCL1 Exon 2 AGGGGTCCAGGAAGCTCAATTC CAAAGGCAGTCACTGAGAGGTATTG 659 
CCL1 Promoter TCAGTCCATCCTATGCCATCTGTC TGTCTCATCAGCCACCTCGTTC 4,228 
CCL1 Prom seqF TCCCAGCTTGCTCAGTTACA - - 
CCL1 Prom seqF2 AGAAGTCTGTGCCCTTGG - - 
CCL1 Prom seqF3 AGAGAAGTCTGTGCCCTTGG - - 
CCL1 Prom seqR - TAAAGGCTCATCCGGTTTTG - 
CCL1 Prom seqR2 - GGTAAAGAGTCAGAAGATTGGG - 
CCL2 Exon 1 TGGAAAAAGTGTCTTGTCCTGACC AGAGTAACTGTGCTGAGTGTGTCCC 589 
CCL2 Exon 2 GCTGGTCATCTGGATTATTGGTCC TGGAGCCATCCTGACTTCAAAC 645 
CCL2 Exon 3 CACCTGGGTGCCTATTCAGAAC GAACTGTGGTTCAAGAGGAAAAGC 544 
CCL2 Promoter 1 CCTTTAGCTGTCTGCCCATTAGG TGCTGAGCAAATGCAGCGTC 818 
CCL2 Promoter 2 ACTCAGCTCAGCCATTTACATGC GCTGGTGTCATACTCACAGAGTGC 662 
CCL2 Promoter 3 TGAGCAGAGGACTGAGCCAAAC AGCAGAGGAGGAGTATTTCGGG 867 
CCL5 Exon 1 CAAAGGGGAAACTGATGAGC CTTGGGGGTGTAGACCTTGA 594 
CCL5 Exon 2 GTTATGGAGCCTGAGCCTTG TGGGCAGGATTCTCTAAGGA 681 
CCL5 Exon 3 ATTTGTTTCTGGCTTGGAGC GTGGTAGAATCTGGGCCCTT 419 
CCL5 Promoter 1 CCTATGGCCAGGATGAAAGA CCTTCATGGTACCTGTGGGA 680 
CCL5 Promoter 2 GGCCTTCAGTGAGATGGGAT CTTTCCCTCATCCACGGTTA 491 
CCL5 Promoter 3 AGCCCAGATCAAATTGTTGC CTCTTACAGCATACTCTACC 550 
CCL20 Exon 1 TGTGTGGGGCTGACCTTTGTATC GCACTTTGGCTTTGTCCTGAAG 760 
CCL20 Exon 2 TCTCAGCACACAAACTGTTGTTCC GGAAGTTTTTGCCTTATTCCAGTCC 558 
CCL20 Exon 3 TTTGTTACATTGCAGAGAAAGGGAG CATTCTTTGTGTTTGTGGTCCAAC 438 
CCL20 Exon 3 seq ACCTCGTCAACTGAAGTGTTTAGT - - 
CCL20 Exon 3a TTTGTTACATTGCAGAGAAAGGGAG CAACCAAATGCTGGATTGCC 604 
CCL20 Exon 4 CACTTTATCAACGGATGGAAGGC TTGGACAAGTCCCAGTGAGGC 440 
CCL20 Promoter 1 TGATATAGGCATCACCAACTCCG TGGGAAGATGCAAAGGTCAGG 799 
CCL20 Promoter 2 GGCAAAAATTATCATGGTGCATGAC GGCTCAAACCTCATCTTCATCTTG 733 
CCL20 Promoter 2a GGCAACAAGAGCAAAATTCTGTCTC GGCTCAAACCTCATCTTCATCTTG 607 
CXCL13 3'STR FAM-AGCATTCAAAGATCCCCAGA GTGATTGTGCCACTGCACTC 400 
CXCL13 Exon 1 TGATGCAGCTGACCTACTGG TGGAATCTGAAAAAGGCTGG 479 
CXCL13 Exon 1a TGACCTACTGGAGACAAAGGCAG TGAAAAAGGCTGGGAATATACAAGC 462 
CXCL13 Exon 2 AGCCAAGGCAAGCAGAAATA GCCTCAGGCTGTAAGGAACA 554 
CXCL13 Exon 3 & 4 TGACCCCATGCTACAAATCA GCACAAAACTAAAACCCGGA 655 
CXCL13 Promoter 1 GCAGTTCAGTGGGTCTGGTT GCTATTGGTGATGGTGGCTT 696 
CXCL13 Promoter 2 CCCTTCCACATGCTAGGGAT CAGCAGCATGAGAAGCAGAG 503 
CXCL13 Promoter 3 GGATGGATAGATGGGGGAGT ATCCCAGGTGCCTCAGTATG 802 
CXCL13 Promoter 3a CTTCCTCCTTCTGTCTATTGCAGG TGGGCTTCCTGGAGTGATTTCC 491 
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APPENDIX B 
SNP DISTRIBUTIONS 
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Table 21:  CXCL13 SNP Distribution 
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